1. Home
  2. DSP vs BNR Comparison

DSP vs BNR Comparison

Compare DSP & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Viant Technology Inc.

DSP

Viant Technology Inc.

HOLD

Current Price

$11.36

Market Cap

198.1M

Sector

Technology

ML Signal

HOLD

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

BUY

Current Price

$22.75

Market Cap

216.9M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
DSP
BNR
Founded
1999
2014
Country
United States
China
Employees
N/A
N/A
Industry
EDP Services
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
198.1M
216.9M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
DSP
BNR
Price
$11.36
$22.75
Analyst Decision
Strong Buy
Analyst Count
8
0
Target Price
$18.50
N/A
AVG Volume (30 Days)
219.1K
52.5K
Earning Date
11-10-2025
11-20-2025
Dividend Yield
N/A
N/A
EPS Growth
29.49
N/A
EPS
0.10
N/A
Revenue
$324,131,000.00
$75,749,382.00
Revenue This Year
$17.79
$136.32
Revenue Next Year
$17.72
N/A
P/E Ratio
$115.77
N/A
Revenue Growth
22.97
5.56
52 Week Low
$8.11
$2.18
52 Week High
$26.33
$24.92

Technical Indicators

Market Signals
Indicator
DSP
BNR
Relative Strength Index (RSI) 48.43 58.46
Support Level $11.42 $19.10
Resistance Level $12.20 $23.52
Average True Range (ATR) 0.39 2.33
MACD -0.12 0.04
Stochastic Oscillator 13.04 71.22

Price Performance

Historical Comparison
DSP
BNR

About DSP Viant Technology Inc.

Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

Share on Social Networks: